Receive The Newest Study Notifications

Abivax Receives Clearance from U.S. FDA to Initiate Clinical Trials with ABX464 to treat Moderate to Severe Ulcerative Colitis

by Lance Smith | Jan 21, 2020 | Study Scavenger Clinical Trial Recruitment Platform

Active U.S. Investigational New Drug (IND) status extends Phase 2b clinical study in moderate to severe Ulcerative Colitis (UC) clinical trial to U.S. patients ABX464 Phase 2b UC trial is already ongoing in 15 European countries and Canada Enrollment of first U.S....

Stealth BioTherapeutics Initiates First-in-Human Study of SBT-272

by Lance Smith | Jan 21, 2020 | Study Scavenger Clinical Trial Recruitment Platform

BOSTON, Jan. 21, 2020 /PRNewswire/ — Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced...

Abivax Receives Clearance from U.S. FDA to Initiate Clinical Trials with ABX464 to treat Moderate to Severe Ulcerative Colitis

by Lance Smith | Jan 20, 2020 | Study Scavenger Clinical Trial Recruitment Platform

Active U.S. Investigational New Drug (IND) status extends Phase 2b clinical study in moderate to severe Ulcerative Colitis (UC) clinical trial to U.S. patients ABX464 Phase 2b UC trial is already ongoing in 15 European countries and Canada Enrollment of first U.S....

Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease

by Lance Smith | Jan 20, 2020 | Study Scavenger Clinical Trial Recruitment Platform

Mayzent® (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease in Europe1 Mayzent addresses an unmet need for SPMS patients with active disease who, until now, did...

Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early

by Lance Smith | Jan 20, 2020 | Study Scavenger Clinical Trial Recruitment Platform

LONDON, Jan 20, 2020 (GLOBE NEWSWIRE via COMTEX) — LONDON, Jan. 20, 2020 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med”) (aim/nasdaq:HCM) today announces that the independent Data Monitoring Committee (“IDMC”) of the...

Three clinical trials announced for Fasenra in eosinophil-driven skin diseases

by Lance Smith | Jan 20, 2020 | Study Scavenger Clinical Trial Recruitment Platform

Fasenra being evaluated in eight eosinophil-driven diseases beyond severe asthma AstraZeneca today announced three new trials for Fasenra (benralizumab) in skin diseases, adding to five trials already underway for the medicine in eosinophil-driven diseases (EDDs)...